Cereno Scientific AB Announces Positive Phase IIa Trial Results for CS1

Cereno Scientific AB, a Swedish biotechnology company listed on the Frankfurt Stock Exchange, has recently presented promising results from the Phase IIa trial of its investigational drug, CS1, at the 5th Baltic Pulmonary Hypertension Conference 2025. The company, which is also traded on the Swedish Stock Exchange under the ticker CRNO B, focuses on developing innovative treatments for rare cardiovascular and pulmonary diseases.

The trial, titled “Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial,” was conducted to evaluate the safety and tolerability of CS1 in patients with pulmonary arterial hypertension (PAH). The study successfully met its primary endpoints, demonstrating that CS1 was well-tolerated without any drug-related serious adverse events.

Key findings from the trial included an improvement in the REVEAL Risk Score 2.0 for 40.9% of patients after 12 weeks of treatment, with an additional 31.8% of patients maintaining a stable score. These results suggest that CS1 has the potential to improve clinical outcomes for patients with PAH.

As of May 8, 2025, Cereno Scientific’s stock closed at 8.91 SEK, with a market capitalization of approximately 2.26 billion SEK. The company’s shares have experienced significant volatility over the past year, reaching a 52-week high of 9.5 SEK on September 29, 2024, and a low of 3.49 SEK on May 15, 2024.

The positive trial results are expected to bolster investor confidence in Cereno Scientific’s pipeline and its commitment to addressing unmet medical needs in the field of rare diseases. The company continues to focus on advancing its innovative therapies through rigorous clinical testing and development.

For more information on Cereno Scientific AB and its ongoing research efforts, investors and stakeholders are encouraged to follow the company’s updates and announcements.